Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly Irinotecan Liposomes with Capecitabine-based Chemoradiation for Rectal Cancer
NCT06300489Phase 1Recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Mar 2024
- Primary completion
- Jan 2025
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nanoliposomal irinotecan in rectal cancer, sponsored by Zhejiang Cancer Hospital. Primary endpoints: Dose-Limiting Toxicity up to 6 months and Maximum Tolerable Dose up to 6 months. Started Mar 2024; status: recruiting.
02
Drugs
nanoliposomal irinotecan
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT06300489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06300489.